OBJECTIVE: Many terminally ill patients enroll in a hospice late in their illness, and recent data indicate decreasing lengths of hospice enrollment, yet we know little about the impact of hospice enrollment length on surviving caregivers. This is the first study the authors know of that examines the association between hospice enrollment length and subsequent major depressive disorder among surviving caregivers. METHOD: The authors conducted a prospective cohort study with 174 primary family caregivers of consecutively enrolled hospice patients with cancer between October 1999 and September 2001. Using data from in-person interviews at the time of enrollment and 6-8 months after the patient's death, they estimated with logistic regression the adjusted risk of major depressive disorder with the Structured Clinical Interview for the DSM-IV axis I modules based on the number of days of hospice care before death. RESULTS: Caregivers of patients enrolled with hospice for 3 or fewer days were significantly more likely to have major depressive disorder at the follow-up interview than caregivers of those with longer hospice enrollment (24.1% versus 9.0%, respectively), adjusted for baseline major depressive disorder and other potential confounders. CONCLUSIONS: The findings identify a target group for whom bereavement services might be most needed. The authors also suggest that earlier hospice enrollment may help reduce the risk of major depressive disorder during the first 6-8 months of bereavement, which raises concerns about recent trends toward decreasing lengths of hospice enrollment before death.
OBJECTIVE: Many terminally ill patients enroll in a hospice late in their illness, and recent data indicate decreasing lengths of hospice enrollment, yet we know little about the impact of hospice enrollment length on surviving caregivers. This is the first study the authors know of that examines the association between hospice enrollment length and subsequent major depressive disorder among surviving caregivers. METHOD: The authors conducted a prospective cohort study with 174 primary family caregivers of consecutively enrolled hospice patients with cancer between October 1999 and September 2001. Using data from in-person interviews at the time of enrollment and 6-8 months after the patient's death, they estimated with logistic regression the adjusted risk of major depressive disorder with the Structured Clinical Interview for the DSM-IV axis I modules based on the number of days of hospice care before death. RESULTS: Caregivers of patients enrolled with hospice for 3 or fewer days were significantly more likely to have major depressive disorder at the follow-up interview than caregivers of those with longer hospice enrollment (24.1% versus 9.0%, respectively), adjusted for baseline major depressive disorder and other potential confounders. CONCLUSIONS: The findings identify a target group for whom bereavement services might be most needed. The authors also suggest that earlier hospice enrollment may help reduce the risk of major depressive disorder during the first 6-8 months of bereavement, which raises concerns about recent trends toward decreasing lengths of hospice enrollment before death.
Authors: Katherine A Ornstein; Melissa D Aldridge; Melissa M Garrido; Rebecca Gorges; Diane E Meier; Amy S Kelley Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873
Authors: Laura P Gelfman; Yolanda Barrón; Stanley Moore; Christopher M Murtaugh; Anuradha Lala; Melissa D Aldridge; Nathan E Goldstein Journal: JACC Heart Fail Date: 2018-08-08 Impact factor: 12.035
Authors: Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Tal Gross; Grace C Hillyer; Dawn L Hershman Journal: Breast Cancer Res Treat Date: 2017-07-27 Impact factor: 4.872
Authors: Amy S Kelley; Partha Deb; Qingling Du; Melissa D Aldridge Carlson; R Sean Morrison Journal: Health Aff (Millwood) Date: 2013-03 Impact factor: 6.301
Authors: Jennifer A Shin; Amanda Parkes; Areej El-Jawahri; Lara Traeger; Helen Knight; Emily R Gallagher; Jennifer S Temel Journal: Palliat Med Date: 2016-03-15 Impact factor: 4.762